PeptideInfo
العربيةGet the app
☰
Neurological & CognitiveNot approved (US)

CDP-Choline

Citicoline

CDP-Choline supplies choline.

Not medical advice. Educational reference only.

Route
Intranasal or injectable (research discussion)
Storage
Keep refrigerated at 2–8 °C and use within 28 days.

What is CDP-Choline?

CDP-Choline, also called citicoline, is a choline-supplying nootropic compound rather than a peptide. It is used in cognitive and neurological support protocols. Its classification as a supplement or drug varies by region; it has no FDA drug approval.

Mechanism of action

Citicoline supplies choline for cognitive and neurological support; it is a non-peptide compound.

Research indications

  • Cognitive Function

    Effective

    Cognitive research examines possible improvements in memory, attention and information processing.

  • Neuroprotection

    Moderate

    Potential neuronal protection includes limiting damage caused by oxidative stress and inflammation.

  • Mood & Anxiety

    Moderate

    Some studies investigate reduced anxiety and more stable mood.

Interactions

  • Stimulants (Modafinil, Adderall)

    Caution

  • MAOIs / SSRIs

    Monitor

  • Racetams

    Caution

  • NAD+

    Compatible

  • BPC-157

    Compatible

How to reconstitute and inject

Diluent: Use bacteriostatic water only; avoid saline because it may cause precipitation.

  1. Take the CDP-Choline vial out of the refrigerator and leave it for 15–20 minutes to reach room temperature.
  2. Disinfect the vial stopper with an alcohol swab. Wait until the alcohol has completely air-dried.
  3. Measure the calculated amount of bacteriostatic water into a sterile syringe. Use only bacteriostatic water; avoid saline because precipitation may occur.
  4. Add the water slowly along the inner wall of the vial. Keep the stream away from the powder itself.
  5. Rotate the vial gently to mix its contents. Never shake it vigorously, because this can degrade the peptide.
  6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is clear and has no color.
  7. Withdraw the calculated dose into an insulin syringe for administration beneath the skin.
  8. Inject into your abdomen, thigh or upper arm. Change the injection site each time to help prevent lipodystrophy.
  9. Refrigerate the mixed solution at 2–8 °C. Use it within 28 days after reconstitution.

What to expect

Week 1–2
Small improvements in mood and attention may emerge, with better sleep appearing early.
Week 2–4
Possible changes include clearer thinking, easier word retrieval and less brain fog.
Week 4–8
Cognitive changes may become more consistent, alongside improved working memory and responses to stress.
Week 8+
Cognitive and neurological effects may continue and can potentially last beyond the end of a cycle. These intervals are research expectations, not established individual outcomes.

Side effects and safety

  • Headache, especially when beginning use
  • Mild restlessness or anxiety with some compounds
  • Irritation of the nasal lining after intranasal administration
  • Disrupted sleep when dosing near bedtime
  • Changes in mood or emotional stability · Rare

CDP-Choline: not approved in the US.

Regulatory status

  • US

    Not approved

    FDA — no drug approval; supplement or drug classification depends on the region.

    Rx required
    No
    503A
    Allowed
    Telehealth
    Available

Frequently asked questions

What is CDP-Choline?

Citicoline supplies choline and is investigated for cognitive and neurological support. It is not a peptide and has no FDA drug approval.

What research applications are being explored for CDP-Choline?

Research examines cognition and neurological support. Discuss any proposed use with a qualified healthcare professional.

Which doses appear in research discussions?

Starting dose: an unspecified low dose once daily, using an intranasal or injectable route. Standard dose: an unspecified standard amount once daily by either route. Neither schedule supplies a numeric dose. Consult a qualified clinician and current literature for dosing guidance specific to the indication.

What safety concerns need consideration?

The dose, administration route and individual response influence adverse effects. Human studies have not fully characterized compound-specific risks. Headache, restlessness, nasal irritation and sleep changes are potential concerns in cognitive-compound discussions. Ask a qualified healthcare professional about individual risk.

References

  1. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). (2012)

    PMID 22691567DOI 10.1016/S0140-6736(12)60813-7

  2. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). (2012)

    PMID 23168823DOI 10.1001/jama.2012.13256

  3. International Citicoline Trial on Acute Stroke (ICTUS) (NCT00331890) (2006)

  4. Citicoline Brain Injury Treatment Trial (COBRIT) (NCT00545662) (2007)